Sanofi $SNY Shares Purchased by NewEdge Advisors LLC

NewEdge Advisors LLC boosted its holdings in shares of Sanofi (NASDAQ:SNY) by 18.6% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 77,501 shares of the company’s stock after purchasing an additional 12,172 shares during the period. NewEdge Advisors LLC’s holdings in Sanofi were worth $3,734,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Flagship Harbor Advisors LLC purchased a new position in shares of Sanofi during the fourth quarter worth about $25,000. Physician Wealth Advisors Inc. raised its stake in Sanofi by 180.5% during the 1st quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock valued at $28,000 after acquiring an additional 379 shares during the last quarter. Leonteq Securities AG lifted its position in Sanofi by 95.8% during the 1st quarter. Leonteq Securities AG now owns 607 shares of the company’s stock worth $29,000 after acquiring an additional 297 shares during the period. Western Wealth Management LLC purchased a new position in shares of Sanofi in the 1st quarter valued at approximately $29,000. Finally, Measured Wealth Private Client Group LLC acquired a new position in shares of Sanofi in the third quarter valued at approximately $29,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on SNY. Argus upgraded Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. BNP Paribas Exane downgraded shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective for the company. in a research report on Monday, April 20th. Wall Street Zen cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Sunday. Morgan Stanley set a $49.00 target price on shares of Sanofi in a report on Wednesday, July 8th. Finally, Weiss Ratings lowered shares of Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, August 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Sanofi currently has a consensus rating of “Hold” and an average price target of $49.50.

Sanofi Stock Performance

Shares of SNY stock opened at $43.71 on Thursday. The stock has a fifty day moving average price of $43.36 and a 200 day moving average price of $44.99. The stock has a market cap of $105.97 billion, a PE ratio of 22.88, a P/E/G ratio of 1.09 and a beta of 0.35. Sanofi has a 1 year low of $40.89 and a 1 year high of $52.68. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.64 and a current ratio of 0.99.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.